JP2020525536A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020525536A5 JP2020525536A5 JP2020517774A JP2020517774A JP2020525536A5 JP 2020525536 A5 JP2020525536 A5 JP 2020525536A5 JP 2020517774 A JP2020517774 A JP 2020517774A JP 2020517774 A JP2020517774 A JP 2020517774A JP 2020525536 A5 JP2020525536 A5 JP 2020525536A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- stimulant
- vector
- cell
- sre
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 89
- 210000004027 cell Anatomy 0.000 claims description 32
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 27
- 239000013598 vector Substances 0.000 claims description 23
- 108091033319 polynucleotide Proteins 0.000 claims description 17
- 239000002157 polynucleotide Substances 0.000 claims description 17
- 102000040430 polynucleotide Human genes 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 230000035772 mutation Effects 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 230000004927 fusion Effects 0.000 claims description 11
- 239000002955 immunomodulating agent Substances 0.000 claims description 11
- 229920001184 polypeptide Polymers 0.000 claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 239000012636 effector Substances 0.000 claims description 10
- 229960000835 tadalafil Drugs 0.000 claims description 10
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims description 10
- 230000004044 response Effects 0.000 claims description 8
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims description 8
- 150000003384 small molecules Chemical group 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- RCJYGWGQCPDYSL-HZPDHXFCSA-N 7-[(3-bromo-4-methoxyphenyl)methyl]-1-ethyl-8-[[(1r,2r)-2-hydroxycyclopentyl]amino]-3-(2-hydroxyethyl)purine-2,6-dione Chemical compound C=1C=C(OC)C(Br)=CC=1CN1C=2C(=O)N(CC)C(=O)N(CCO)C=2N=C1N[C@@H]1CCC[C@H]1O RCJYGWGQCPDYSL-HZPDHXFCSA-N 0.000 claims description 4
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 claims description 4
- 229960000307 avanafil Drugs 0.000 claims description 4
- WEAJZXNPAWBCOA-INIZCTEOSA-N avanafil Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(N2[C@@H](CCC2)CO)=NC=C1C(=O)NCC1=NC=CC=N1 WEAJZXNPAWBCOA-INIZCTEOSA-N 0.000 claims description 4
- 229950004399 beminafil Drugs 0.000 claims description 4
- ZISFCTXLAXIEMV-UHFFFAOYSA-N benzamidenafil Chemical compound C1=C(OC)C(OC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1NC(C)CO ZISFCTXLAXIEMV-UHFFFAOYSA-N 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- KJJPAVCZQWWWMM-WKILWMFISA-N chembl2107736 Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC([C@@H]2CC[C@H](CC2)C(O)=O)=NC2=C1C1=CC=CC=C1S2 KJJPAVCZQWWWMM-WKILWMFISA-N 0.000 claims description 4
- 229950003418 dasantafil Drugs 0.000 claims description 4
- 230000004068 intracellular signaling Effects 0.000 claims description 4
- -1 rodenafil Chemical compound 0.000 claims description 4
- 229960003310 sildenafil Drugs 0.000 claims description 4
- IYFNEFQTYQPVOC-UHFFFAOYSA-N udenafil Chemical compound C1=C(C=2NC=3C(CCC)=NN(C)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)NCCC1CCCN1C IYFNEFQTYQPVOC-UHFFFAOYSA-N 0.000 claims description 4
- 229960000438 udenafil Drugs 0.000 claims description 4
- 229960002381 vardenafil Drugs 0.000 claims description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 3
- 108091027981 Response element Proteins 0.000 claims description 3
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 claims description 3
- 101710095785 cGMP-specific 3',5'-cyclic phosphodiesterase Proteins 0.000 claims description 3
- 230000003197 catalytic effect Effects 0.000 claims description 3
- 230000000368 destabilizing effect Effects 0.000 claims description 3
- 210000002865 immune cell Anatomy 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000013603 viral vector Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 239000000021 stimulant Substances 0.000 claims 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 2
- 241001430294 unidentified retrovirus Species 0.000 claims 2
- 239000013607 AAV vector Substances 0.000 claims 1
- 241001663880 Gammaretrovirus Species 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 1
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 1
- 229950002245 mirodenafil Drugs 0.000 claims 1
- MIJFNYMSCFYZNY-UHFFFAOYSA-N mirodenafil Chemical compound C1=C(C=2NC=3C(CCC)=CN(CC)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)N1CCN(CCO)CC1 MIJFNYMSCFYZNY-UHFFFAOYSA-N 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 description 20
- 230000037396 body weight Effects 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 102000017578 LAG3 Human genes 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 241001193851 Zeta Species 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023133318A JP2023144094A (ja) | 2017-06-12 | 2023-08-18 | 免疫療法のためのｐｄｅ５組成物及び方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762518078P | 2017-06-12 | 2017-06-12 | |
| US62/518,078 | 2017-06-12 | ||
| US201762523850P | 2017-06-23 | 2017-06-23 | |
| US201762523862P | 2017-06-23 | 2017-06-23 | |
| US62/523,850 | 2017-06-23 | ||
| US62/523,862 | 2017-06-23 | ||
| US201762555313P | 2017-09-07 | 2017-09-07 | |
| US62/555,313 | 2017-09-07 | ||
| PCT/US2018/037005 WO2018231759A1 (en) | 2017-06-12 | 2018-06-12 | Pde5 compositions and methods for immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023133318A Division JP2023144094A (ja) | 2017-06-12 | 2023-08-18 | 免疫療法のためのｐｄｅ５組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020525536A JP2020525536A (ja) | 2020-08-27 |
| JP2020525536A5 true JP2020525536A5 (enExample) | 2021-07-26 |
| JP7362596B2 JP7362596B2 (ja) | 2023-10-17 |
Family
ID=64660633
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517774A Active JP7362596B2 (ja) | 2017-06-12 | 2018-06-12 | 免疫療法のためのｐｄｅ５組成物及び方法 |
| JP2023133318A Pending JP2023144094A (ja) | 2017-06-12 | 2023-08-18 | 免疫療法のためのｐｄｅ５組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023133318A Pending JP2023144094A (ja) | 2017-06-12 | 2023-08-18 | 免疫療法のためのｐｄｅ５組成物及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11241485B2 (enExample) |
| EP (1) | EP3638289A4 (enExample) |
| JP (2) | JP7362596B2 (enExample) |
| CN (1) | CN111107866A (enExample) |
| CA (1) | CA3067211A1 (enExample) |
| MA (1) | MA49403A (enExample) |
| MX (1) | MX2019014960A (enExample) |
| SG (1) | SG11201912010XA (enExample) |
| WO (1) | WO2018231759A1 (enExample) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CN105939767B (zh) | 2014-01-08 | 2018-04-06 | 弗洛设计声能学公司 | 具有双声电泳腔的声电泳装置 |
| WO2016100232A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| AU2018227583B2 (en) | 2017-03-03 | 2023-06-01 | Obsidian Therapeutics, Inc. | CD19 compositions and methods for immunotherapy |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| KR20200035235A (ko) * | 2017-05-23 | 2020-04-02 | 바이오바이트 오스트레일리아 피티와이 엘티디 | 아르트로스피라로부터의 추출물들 및 그 용도들 |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| US11241485B2 (en) | 2017-06-12 | 2022-02-08 | Obsidian Therapeutics, Inc. | PDE5 compositions and methods for immunotherapy |
| WO2018237323A1 (en) * | 2017-06-23 | 2018-12-27 | The Board Of Trustees Of The Leland Stanford Junior University | Pde5a destabilizing domains |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| CN114900773A (zh) | 2017-12-14 | 2022-08-12 | 弗洛设计声能学公司 | 声泳系统及其操作方法、控制声换能器及声学系统的方法 |
| US12227756B2 (en) | 2018-04-18 | 2025-02-18 | Ucl Business Ltd | Engineered regulatory T cell |
| US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| US12247084B2 (en) | 2018-06-14 | 2025-03-11 | 2Seventy Bio, Inc. | Anti-BCMA CAR antibodies, conjugates, and methods of use |
| EP4578507A3 (en) | 2018-11-01 | 2025-11-12 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
| WO2020123716A1 (en) * | 2018-12-11 | 2020-06-18 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| AU2020218446B2 (en) * | 2019-02-04 | 2023-05-25 | National University Corporation Ehime University | "CAR LIBRARY AND scFv MANUFACTURING METHOD |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| BR112021017770A2 (pt) * | 2019-03-08 | 2021-11-16 | Obsidian Therapeutics Inc | Composições e métodos de cd40l para regulação ajustável |
| WO2020210665A1 (en) * | 2019-04-12 | 2020-10-15 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors with cd20 safety switch |
| US12617866B2 (en) | 2019-05-08 | 2026-05-05 | Memorial Sloan Kettering Cancer Center | Humanized antibodies to mucin-16 and methods of use thereof |
| AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| CA3141614A1 (en) * | 2019-05-24 | 2020-12-03 | Memorial Sloan Kettering Cancer Center | Anti-glypican-3 antibodies and uses thereof |
| WO2020252404A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| AU2020331963A1 (en) * | 2019-08-19 | 2022-03-03 | Elpis Biopharmaceuticals | Anti-CD19 antibodies and uses thereof |
| US20230049954A1 (en) * | 2019-09-06 | 2023-02-16 | The Regents Of The University Of California | Chimeric antigen receptors and related methods and compositions for the treatment of cancer |
| CN114651003A (zh) * | 2019-09-10 | 2022-06-21 | 黑曜石疗法公司 | 用于可调调节的ca2-il15融合蛋白 |
| WO2021072353A1 (en) * | 2019-10-11 | 2021-04-15 | The Regents Of The University Of California | Chimeric antigen receptors against human cytomegalovirus |
| EP4041769A1 (en) * | 2019-12-12 | 2022-08-17 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Antibody-drug conjugates specific for cd276 and uses thereof |
| EP4076522A4 (en) * | 2019-12-16 | 2024-04-10 | 2seventy bio, Inc. | Anti-bcma car antibodies, conjugates, and methods of use |
| CN115135672A (zh) * | 2019-12-20 | 2022-09-30 | 波赛达治疗公司 | 抗muc1组合物和使用方法 |
| AU2021205416B2 (en) | 2020-01-08 | 2026-08-06 | Obsidian Therapeutics, Inc. | Compositions and methods for tunable regulation of transcription |
| WO2021167723A1 (en) * | 2020-02-17 | 2021-08-26 | Board Of Regents, The University Of Texas System | Chimeric scavenger receptors targeted to phosphorylated tau (ptau) and uses thereof |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| US20230124467A1 (en) * | 2020-03-03 | 2023-04-20 | Mios Pharmaceuticals Limited | Compounds and methods for treating diseases and/or conditions caused by coronavirus |
| EP4127208A4 (en) * | 2020-04-03 | 2024-06-05 | University of Cincinnati | Secreted phosphorylated heat shock protein-70 as a biomarker for treating and diagnosing cancer |
| WO2021216686A1 (en) * | 2020-04-21 | 2021-10-28 | Arizona Board Of Regents On Behalf Of Arizona State University | Treating and curing covid-19 infection utilizing a laser |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| MX2022015586A (es) * | 2020-06-12 | 2023-03-15 | Nkarta Inc | Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70. |
| WO2021262773A1 (en) | 2020-06-22 | 2021-12-30 | Obsidian Therapeutics, Inc. | Compositions and methods for tunable regulation of cas nucleases |
| WO2022006588A1 (en) * | 2020-06-29 | 2022-01-06 | Trustees Of Tufts College | Il-38 and analogues thereof for treatment of neuro-inflammatory and neurodegenerative diseases |
| US11508453B2 (en) * | 2020-08-18 | 2022-11-22 | Micron Technology, Inc. | Encoding test data of microelectronic devices, and related methods, devices, and systems |
| GB202013477D0 (en) * | 2020-08-27 | 2020-10-14 | Quell Therapeutics Ltd | Nucleic acid constructs for expressing polypeptides in cells |
| CN114516914B (zh) * | 2020-11-19 | 2023-04-28 | 东莞市朋志生物科技有限公司 | 抗n末端脑钠肽前体的抗体和检测n末端脑钠肽前体的试剂和试剂盒 |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| WO2022155500A1 (en) * | 2021-01-14 | 2022-07-21 | Senti Biosciences, Inc. | Secretable payload regulation |
| JP7893814B2 (ja) | 2021-01-19 | 2026-07-22 | オブシディアン セラピューティクス， インコーポレイテッド | Ｔ細胞及び腫瘍浸潤リンパ球の拡張のための組成物及び方法 |
| EP4301785A4 (en) | 2021-03-05 | 2025-04-23 | Atreca, Inc. | ANTI-EPHA2 ANTIBODIES |
| EP4319794A4 (en) * | 2021-04-08 | 2025-03-12 | Artiva Biotherapeutics, Inc. | CHIMERIC ANTIGEN RECEPTOR COMPRISING AN ANTI-CD19 ANTIBODY OR AN ANTIGEN-BINDING FRAGMENT THEREOF AND NATURAL KILLER CELLS COMPRISING SAME |
| WO2022232392A2 (en) * | 2021-04-28 | 2022-11-03 | Lyvgen Biopharma Holdings Limited | Bi-specific antibodies comprising anti-b7h3 binding molecules |
| CN117425670A (zh) * | 2021-05-19 | 2024-01-19 | 细胞编辑有限责任公司 | 双特异性嵌合抗原受体和表达此类双特异性嵌合抗原受体的基因工程化免疫细胞 |
| KR20240035506A (ko) * | 2021-07-16 | 2024-03-15 | 노일 이뮨 바이오테크 가부시키가이샤 | 키메라 항원 수용체, 상기 수용체를 발현하는 세포, 상기 세포를 포함하는 의약 조성물, 상기 세포의 제조 방법, 및 상기 키메라 항원 수용체를 코딩하는 염기서열을 포함하는 폴리뉴클레오티드 또는 벡터 |
| CN113564184B (zh) * | 2021-07-16 | 2023-04-18 | 昆明理工大学 | 一种天麻谷氨酰胺合成酶基因及其应用 |
| WO2023009700A2 (en) | 2021-07-29 | 2023-02-02 | Takeda Pharmaceutical Company Limited | Car-expressing immune cells that specifically target mesothelin and uses thereof |
| US12410252B2 (en) * | 2021-09-10 | 2025-09-09 | Trustees Of Tufts College | Anti-PD-1 immunoglobulin polypeptides and uses thereof |
| KR20240099267A (ko) | 2021-10-18 | 2024-06-28 | 옵시디안 테라퓨틱스, 인크. | 폴리펩티드 페이로드의 기능/풍부성 및 전달의 조절을 위한 조성물 및 시스템 |
| EP4466010A1 (en) | 2022-01-18 | 2024-11-27 | Obsidian Therapeutics, Inc. | Methods for identifying and using allogeneic tumor infiltrating lymphocytes to treat cancer |
| CN114606323B (zh) * | 2022-04-24 | 2023-11-10 | 深圳大学 | 一种识别胃癌干细胞的标志物lgsn作为胃癌诊断和治疗靶标的应用 |
| KR20250018168A (ko) * | 2022-04-28 | 2025-02-04 | 이매틱스 유에스 인코포레이티드 | 막-결합된 il-15, cd8 폴리펩티드, 세포, 조성물, 및 이의 사용 방법 |
| CN114591431B (zh) * | 2022-05-11 | 2022-08-12 | 迈威(上海)生物科技股份有限公司 | 抗人gas6抗体或其抗原结合片段及其应用 |
| CA3260584A1 (en) | 2022-07-05 | 2024-01-11 | Neomics Pharmaceuticals Llc | CHIMERIC ANTIGENIC RECEPTOR COMPRISING A BCMA NANOBODY LINKED TO A CHIMERIC INTRACELLULAR SIGNALING DOMAIN |
| EP4374872A1 (en) * | 2022-11-22 | 2024-05-29 | Koninklijke Philips N.V. | Pde enhanced car-t cells |
| CN117482245B (zh) * | 2022-12-30 | 2024-10-29 | 英百瑞(杭州)生物医药有限公司 | 抗5t4抗体-自然杀伤细胞偶联物及其用途 |
| CN121039155A (zh) * | 2023-02-09 | 2025-11-28 | 星尘生物科技(上海)有限公司 | 一种嵌合抗原受体及其应用 |
| CN116004547B (zh) * | 2023-03-06 | 2025-04-25 | 浙江康佰裕生物科技有限公司 | 一种辐照car-t细胞及其制备方法与应用 |
| EP4474016A1 (en) | 2023-06-07 | 2024-12-11 | Julius-Maximilians-Universität Würzburg | Strategies to target extracellularly accessible ras protein |
| US12649790B2 (en) | 2023-07-03 | 2026-06-09 | Medicovestor, Inc. | Proteins that bind SP17 including fully-human anti-SP17 antibodies |
| EP4771044A1 (en) * | 2023-09-01 | 2026-07-08 | Institute for Environmental Health, Inc. | Variably deamidated gluten polypeptides and antibodies against same |
| IL326971A (en) * | 2023-09-05 | 2026-05-01 | Michele Pitaro | Single-chain variable fragment and molecules derived therefrom that bind the trvb5-1 fragment of the β chain of the human T-cell receptor |
| EP4784170A1 (en) * | 2023-09-25 | 2026-08-05 | Myris Therapeutics, Inc. | Methods for and compositions of non-peg bioconjugates with ultra-high drug-to-agent ratio |
| CN117406222A (zh) * | 2023-10-24 | 2024-01-16 | 西安电子科技大学 | 一种基于sar的三维成像的补偿方法 |
| CN122459330A (zh) | 2023-12-08 | 2026-07-24 | 黑曜石疗法公司 | 使用活化t细胞核因子(nfat)反应元件增强有效载荷调控的组合物和方法 |
| US12600795B2 (en) | 2023-12-26 | 2026-04-14 | Medicovestor, Inc. | Oligomeric IgG for immunotherapeutics and diagnostics |
| US12673991B2 (en) | 2023-12-26 | 2026-07-07 | Medicovestor, Inc. | Methods of crosslinking IgG |
| US12121587B1 (en) | 2023-12-26 | 2024-10-22 | Medicovestor, Inc. | Dimeric antibodies |
| AU2024415858A1 (en) | 2023-12-27 | 2026-07-16 | Obsidian Therapeutics, Inc. | Compositions and methods for tunable regulation of il15 and light |
| WO2026078631A2 (en) | 2024-10-10 | 2026-04-16 | University Of Lausanne | Switchable chimeric antigen receptors |
| WO2026120207A1 (en) | 2024-12-06 | 2026-06-11 | Bumm Ug | Detection methods and combination therapies of cells with extracellular ras expression |
| CN119930817B (zh) * | 2024-12-24 | 2025-12-02 | 国科大杭州高等研究院 | Tigit全人源抗体及其制备方法与应用 |
| WO2026161343A1 (en) | 2025-01-21 | 2026-07-30 | Obsidian Therapeutics, Inc. | Compositions and methods for tunable regulation of rnai |
| CN121987785A (zh) * | 2026-04-10 | 2026-05-08 | 天津医科大学总医院 | 胆固醇合成酶在制备用于增强car-t细胞及其衍生物杀伤功能的产品中的应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6189999A (en) * | 1998-10-15 | 2000-05-08 | Bioimage A/S | Specific therapeutic interventions obtained by interference with redistribution and/or targetting |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| US20040038373A1 (en) | 2001-12-07 | 2004-02-26 | Platz Matthew S. | Apoptotic EBV-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferative disorder |
| US20050048573A1 (en) | 2003-02-03 | 2005-03-03 | Plexxikon, Inc. | PDE5A crystal structure and uses |
| JP2008500824A (ja) | 2004-05-28 | 2008-01-17 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｐｄｅ５モジュレーターの同定方法 |
| WO2007142929A2 (en) | 2006-05-31 | 2007-12-13 | The University Of North Carolina At Chapel Hill | Novel pde4 inhibitors |
| US8173792B2 (en) | 2007-02-09 | 2012-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells using synthetic small molecules |
| US8530636B2 (en) | 2008-05-07 | 2013-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells in vivo using synthetic small molecules |
| JP2012513464A (ja) | 2008-12-23 | 2012-06-14 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | ホスホジエステラーゼ阻害剤及びその使用 |
| SG10201806573TA (en) | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| US20140255361A1 (en) | 2013-03-07 | 2014-09-11 | The Board Of Trustees Of The Leland Stanford Junior University | Estrogen-receptor based ligand system for regulating protein stability |
| UY35468A (es) * | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| SG11201702295UA (en) | 2014-09-22 | 2017-04-27 | Intrexon Corp | Improved therapeutic control of heterodimeric and single chain forms of interleukin-12 |
| US9766255B2 (en) | 2015-01-12 | 2017-09-19 | President And Fellows Of Harvard College | Biosensors engineered from conditionally stable ligand-binding domains |
| TWI833684B (zh) | 2015-06-25 | 2024-03-01 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體（ｃａｒ）、組合物及其使用方法 |
| CA2994969A1 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| US11052111B2 (en) | 2015-12-08 | 2021-07-06 | Chimera Bioengineering, Inc. | Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| WO2017210617A2 (en) | 2016-06-02 | 2017-12-07 | Porter, David, L. | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
| WO2018161038A1 (en) | 2017-03-03 | 2018-09-07 | Obsidian Therapeutics, Inc. | Il12 compositions and methods for immunotherapy |
| CN110913954A (zh) | 2017-03-03 | 2020-03-24 | 黑曜石疗法公司 | 免疫疗法的组合物和方法 |
| AU2018227583B2 (en) | 2017-03-03 | 2023-06-01 | Obsidian Therapeutics, Inc. | CD19 compositions and methods for immunotherapy |
| WO2018161026A1 (en) | 2017-03-03 | 2018-09-07 | Obsidian Therapeutics, Inc. | Il15 compositions and methods for immunotherapy |
| US11241485B2 (en) | 2017-06-12 | 2022-02-08 | Obsidian Therapeutics, Inc. | PDE5 compositions and methods for immunotherapy |
| WO2018237323A1 (en) * | 2017-06-23 | 2018-12-27 | The Board Of Trustees Of The Leland Stanford Junior University | Pde5a destabilizing domains |
-
2018
- 2018-06-12 US US16/621,593 patent/US11241485B2/en not_active Expired - Fee Related
- 2018-06-12 CN CN201880051747.6A patent/CN111107866A/zh active Pending
- 2018-06-12 MA MA049403A patent/MA49403A/fr unknown
- 2018-06-12 SG SG11201912010XA patent/SG11201912010XA/en unknown
- 2018-06-12 MX MX2019014960A patent/MX2019014960A/es unknown
- 2018-06-12 JP JP2020517774A patent/JP7362596B2/ja active Active
- 2018-06-12 CA CA3067211A patent/CA3067211A1/en active Pending
- 2018-06-12 WO PCT/US2018/037005 patent/WO2018231759A1/en not_active Ceased
- 2018-06-12 EP EP18817018.7A patent/EP3638289A4/en active Pending
-
2022
- 2022-02-01 US US17/649,592 patent/US11666642B2/en active Active
-
2023
- 2023-08-18 JP JP2023133318A patent/JP2023144094A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12612447B2 (en) | April and BAFF inhibitory immunomodulatory proteins and methods of use thereof | |
| JP2020511529A5 (enExample) | ||
| US10865382B2 (en) | Reducing immune tolerance induced by PD-L1 | |
| AU2020336131B2 (en) | Chimeric cytokine receptors comprising TGF beta binding domains | |
| JP7386083B2 (ja) | Ｃｄ８０バリアント免疫調節タンパク質及びその使用 | |
| JP7282760B2 (ja) | バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法 | |
| US20210177951A1 (en) | Engineered cells & methods | |
| US20230071889A1 (en) | Bifunctional anti-pd-1/il-7 molecule | |
| CA3087149A1 (en) | Multi-domain immunomodulatory proteins and methods of use thereof | |
| JP2022543742A5 (enExample) | ||
| JP2017538710A5 (enExample) | ||
| JP2017522882A5 (enExample) | ||
| US11773384B2 (en) | Chimeric antigen receptor (CAR) and T cell receptor (TCR) modified T cells | |
| US20220133792A1 (en) | Signaling platforms for chimeric antigen receptor t cells | |
| US20240317815A1 (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| JP2023539591A5 (enExample) | ||
| JP2022513372A5 (enExample) | ||
| US20230321239A1 (en) | Chimeric antigen receptor t cells for treating autoimmunity | |
| JP2022526720A5 (enExample) | ||
| JP2022550120A5 (enExample) | ||
| WO2025081163A1 (en) | Compositions for the treatment of cancer | |
| TW202436341A (zh) | 嵌合抗原受體及抗體—ｎｋｇ２ｄ配位體域融合蛋白 | |
| JP2025540251A (ja) | 血液癌の治療において使用するためのキット | |
| CN121986120A (zh) | 双特异性多肽分子 | |
| WO2025117851A1 (en) | Meso-fap with adam17 inhibitor or itk inhibitor |